The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Nonalcoholic fatty liver disease (NAFLD) encompasses a broad spectrum of pathological hepatic conditions ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), which may predispose to liver cirrhosis and hepatocellular carcinoma (HCC). Due to the epidemic obesity, NAFLD is representing a global health issue and the leading cause of liver damage worldwide. The pathogenesis of NAFLD is closely related to insulin resistance (IR), adiposity and physical inactivity as well as genetic and epigenetic factors corroborate to the development and progression of hepatic steatosis and liver injury. Emerging evidence has outlined the implication of gut microbiota and gut-derived endotoxins as actively contributors to NAFLD pathophysiology probably due to the tight anatomo-functional crosstalk between the gut and the liver. Obesity, nutrition and environmental factors might alter intestinal permeability producing a favorable micro-environment for bacterial overgrowth, mucosal inflammation and translocation of both invasive pathogens and harmful byproducts, which, in turn, influence hepatic fat composition and exacerbated pro-inflammatory and fibrotic processes. To date, no therapeutic interventions are available for NAFLD prevention and management, except for modifications in lifestyle, diet and physical exercise even though they show discouraging results due to the poor compliance of patients. The premise of this review is to discuss the role of gut–liver axis in NAFLD and emphasize the beneficial effects of probiotics on gut microbiota composition as a novel attractive therapeutic strategy to introduce in clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evolution of mammals and their gut microbes
Ley, R. E., Hamady, M., Lozupone, C., Turnbaugh, P. J., Ramey, R. R., Bircher, J. S., Schlegel, M. L., Tucker, T. A., Schrenzel, M. D., Knight, R., et al. (2008) · Science · doi:10.1126/science.1155725 · Cited by 3,747
The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
Buzzetti, E., Pinzani, M., & Tsochatzis, E. A. (2016) · Metabolism · doi:10.1016/j.metabol.2015.12.012 · Cited by 3,119
Topping, D. L., & Clifton, P. M. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.3.1031 · Cited by 3,091
Gut Microbiota in Human Adults with Type 2 Diabetes Differs from Non-Diabetic Adults
Larsen, N., Vogensen, F. K., van den Berg, F. W. J., Nielsen, D. S., Andreasen, A. S., Pedersen, B. K., Al-Soud, W. A., Sørensen, S. J., Hansen, L. H., & Jakobsen, M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009085 · Cited by 2,952 · cited 3×
“NAFLD is broadly spread in Western countries, affecting between 20% and 40% of the adult population, possibly due to the epidemics of obesity and type 2 diabetes mellitus (T2DM) [3].”
BackgroundTurnbaugh, P. J., Bäckhed, F., Fulton, L., & Gordon, J. I. (2008) · Cell Host & Microbe · doi:10.1016/j.chom.2008.02.015 · Cited by 2,915
Mechanisms underlying the resistance to diet-induced obesity in germ-free mice
Bäckhed, F., Manchester, J. K., Semenkovich, C. F., & Gordon, J. I. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605374104 · Cited by 2,615 · cited 2×
“Several lines of evidence indicate that intestinal flora composition and function play a paramount role in the development of obesity and NAFLD [37] and preclinical models are particularly worthwhile in the understanding of the implications of enteric dysbiosis and bacterial overgrowth in the pathophysiology of these…”
BackgroundInfluence of diet on the gut microbiome and implications for human health
Singh, R. K., Chang, H.-W., Yan, D., Lee, K. M., Ucmak, D., Wong, K., Abrouk, M., Farahnik, B., Nakamura, M., Zhu, T. H., et al. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1175-y · Cited by 2,599 · cited 1×
“Indeed, a diet enriched in animal fat and sugars as well as the Western diet may predispose to bacterial overgrowth, immune system activation and mucosal inflammation both in preclinical [30,31] and clinical studies [32,33].”
BackgroundInflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
Henao-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal, W. Z., Strowig, T., Thaiss, C. A., Kau, A. L., Eisenbarth, S. C., Jurczak, M. J., et al. (2012) · Nature · doi:10.1038/nature10809 · Cited by 2,435 · cited 1×
“Specifically, Barnesiella intestinihominis, which was previously related to increased hepatic steatosis and inflammation [43], was found increased in HFD mice, whereas Bacteroides vulgatus was reduced, as well as in patients affected by diabetes [44].”
BackgroundEffects of probiotics, prebiotics, and synbiotics on human health
Markowiak, P., & Śliżewska, K. (2017) · Nutrients · doi:10.3390/nu9091021 · Cited by 2,401 · cited 1×
“, high survival rate in finished products) [110].”
BackgroundAlterations of the human gut microbiome in liver cirrhosis
Qin, N., Yang, F., Li, A., Prifti, E., Chen, Y., Shao, L., Guo, J., Le Chatelier, E., Yao, J., Wu, L., et al. (2014) · Nature · doi:10.1038/nature13568 · Cited by 2,177
Non-alcoholic fatty liver disease - a global public health perspective
Younossi, Z. M. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.10.033 · Cited by 2,149
Ivanov, I. I., Frutos, R. D. L., Manel, N., Yoshinaga, K., Rifkin, D. B., Sartor, R. B., Finlay, B. B., & Littman, D. R. (2008) · Cell Host & Microbe · doi:10.1016/j.chom.2008.09.009 · Cited by 1,770
Zhu, L., Baker, S. S., Gill, C., Liu, W., Alkhouri, R., Baker, R. D., & Gill, S. R. (2013) · Hepatology · doi:10.1002/hep.26093 · Cited by 1,708 · cited 10×
“, Escherichia coli abundance), are able to stimulate hepatic Kupffer cells to produce pro-inflammatory cytokines with similar mechanisms occurring in ALD [10,57].”
BackgroundInfluentialSchwabe, R. F., & Jobin, C. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3610 · Cited by 1,689
Boursier, J., Mueller, O., Barret, M., Machado, M., Fizanne, L., Araujo‐Perez, F., Guy, C. D., Seed, P. C., Rawls, J. F., David, L. A., et al. (2016) · Hepatology · doi:10.1002/hep.28356 · Cited by 1,483 · cited 2×
“Thus, the degree of NAFLD is correlated to dysbiosis and to modifications of metabolic properties of intestinal flora [53].”
BackgroundPowell, E. E., Cooksley, G. W. E., Hanson, R., Searle, J., Halliday, J. W., & Powell, L. W. (1990) · Hepatology · doi:10.1002/hep.1840110114 · Cited by 1,473 · cited 1×
“Indeed, fatty liver is highly prevalent in obese patients and the 20%–30% of pathologically obese individuals show histological signs of necroinflammation and fibrosis [92,93], possibly even for diet-induced derangement of barrier integrity.”
BackgroundImpact of the gut microbiota on inflammation, obesity, and metabolic disease
Boulangé, C. L., Neves, A. L., Chilloux, J., Nicholson, J. K., & Dumas, M.-E. (2016) · Genome Medicine · doi:10.1186/s13073-016-0303-2 · Cited by 1,438
Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease
Miele, L., Valenza, V., La Torre, G., Montalto, M., Cammarota, G., Ricci, R., Mascianà, R., Forgione, A., Gabrieli, M. L., Perotti, G., et al. (2009) · Hepatology · doi:10.1002/hep.22848 · Cited by 1,434 · cited 2×
“demonstrated that NAFLD patients had a significantly increased gut permeability compared to healthy subjects and the prevalence of small intestinal bacterial overgrowth strictly correlated with the severity of steatosis, but not with lobular inflammation, ballooning and fibrosis [51].”
BackgroundPromotion of Hepatocellular Carcinoma by the Intestinal Microbiota and TLR4
Dapito, D. H., Mencin, A., Gwak, G.-Y., Pradere, J.-P., Jang, M.-K., Mederacke, I., Caviglia, J. M., Khiabanian, H., Adeyemi, A., Bataller, R., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.007 · Cited by 1,346
The role of the gut microbiota in NAFLD
Leung, C., Rivera, L., Furness, J. B., & Angus, P. W. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.85 · Cited by 1,020
Kassinen, A., Krogius-Kurikka, L., Mäkivuokko, H., Rinttilä, T., Paulin, L., Corander, J., Malinen, E., Apajalahti, J., & Palva, A. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.005 · Cited by 1,002
Interactions Between the Intestinal Microbiome and Liver Diseases
Schnabl, B., & Brenner, D. A. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.01.020 · Cited by 971 · cited 1×
“In particular, LPS-induced TLR-4 cascade in hepatocytes, Kupffer cells and hepatic stellate cells (HSCs) leading to elevated systemic levels of tumor necrosis factor alpha (TNF-α) and interleukin 6 (IL6) via nuclear receptor kappa B (NF-kB) thus promoting IR, inflammation and fibrosis [9,76].”
BackgroundChávez-Talavera, O., Tailleux, A., Lefebvre, P., & Staels, B. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.01.055 · Cited by 970
Cani, P. D., Osto, M., Geurts, L., & Everard, A. (2012) · Gut Microbes · doi:10.4161/gmic.19625 · Cited by 864
Intestinal microbiota in patients with nonalcoholic fatty liver disease
Mouzaki, M., Comelli, E. M., Arendt, B. M., Bonengel, J., Fung, S. K., Fischer, S. E., McGilvray, I. D., & Allard, J. P. (2013) · Hepatology · doi:10.1002/hep.26319 · Cited by 749 · cited 1×
“[54] may reflect the diversity in age, BMI, environmental and dietary factors of the two study cohorts.”
BackgroundDing, S., Chi, M. M., Scull, B. P., Rigby, R., Schwerbrock, N. M. J., Magness, S., Jobin, C., & Lund, P. K. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012191 · Cited by 713
Del Chierico, F., Nobili, V., Vernocchi, P., Russo, A., De Stefanis, C., Gnani, D., Furlanello, C., Zandonà, A., Paci, P., Capuani, G., et al. (2017) · Hepatology · doi:10.1002/hep.28572 · Cited by 696
Raman, M., Ahmed, I., Gillevet, P. M., Probert, C. S., Ratcliffe, N. M., Smith, S., Greenwood, R., Sikaroodi, M., Lam, V., Crotty, P., et al. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.02.015 · Cited by 672
Rabot, S., Membrez, M., Bruneau, A., Gérard, P., Harach, T., Moser, M., Raymond, F., Mansourian, R., & Chou, C. J. (2010) · The FASEB Journal · doi:10.1096/fj.10.164921 · Cited by 610 · cited 1×
“Finally, germ-free mice were also reported to be resistant to high-fat diet (HFD)-induced IR, showing enhanced hepatic and adipose tissue insulin sensitivity and fecal lipid excretion [41], revealing that insulin resistance index (HOMA-IR) is transmissible [38].”
BackgroundMilosevic, I., Vujovic, A., Barac, A., Djelic, M., Korac, M., Radovanovic Spurnic, A., Gmizic, I., Stevanovic, O., Djordjevic, V., Lekic, N., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020395 · Cited by 551 · cited 1×
“, obeticholic acids) have been proposed as they are able to reduce hepatic steatosis and necroinflammation [88,89].”
BackgroundMartinez-Medina, M., Denizot, J., Dreux, N., Robin, F., Billard, E., Bonnet, R., Darfeuille-Michaud, A., & Barnich, N. (2014) · Gut · doi:10.1136/gutjnl-2012-304119 · Cited by 539
The role of the microbiome in NAFLD and NASH
Kolodziejczyk, A. A., Zheng, D., Shibolet, O., & Elinav, E. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201809302 · Cited by 523
Alisi, A., Bedogni, G., Baviera, G., Giorgio, V., Porro, E., Paris, C., Giammaria, P., Reali, L., Anania, F., & Nobili, V. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12758 · Cited by 471 · cited 1×
“In a double-blind RCT (NCT01650025), in which were enrolled 48 pediatric NAFLD, 4 months VSL#3 supplementation improves severity of NAFLD as a consequence of VSL#3-induced eubiosis [138].”
BackgroundZhou, D., Pan, Q., Xin, F.-Z., Zhang, R.-N., He, C.-X., Chen, G.-Y., Liu, C., Chen, Y.-W., & Fan, J.-G. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i1.60 · Cited by 441
Hold, G. L. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i5.1192 · Cited by 365
Effects of probiotics on nonalcoholic fatty liver disease: A meta-analysis
Ma, Y.-Y. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i40.6911 · Cited by 352
Yu, L.-X., Yan, H.-X., Liu, Q., Yang, W., Wu, H.-P., Dong, W., Tang, L., Lin, Y., He, Y.-Q., Zou, S.-S., et al. (2010) · Hepatology · doi:10.1002/hep.23845 · Cited by 349
Lee, H.-Y., Park, J.-H., Seok, S.-H., Baek, M.-W., Kim, D.-J., Lee, K.-E., Paek, K.-S., Lee, Y., & Park, J.-H. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2006.05.007 · Cited by 342
A Gut Microbiome Signature for Cirrhosis Due to Nonalcoholic Fatty Liver Disease
Caussy, C., Tripathi, A., Humphrey, G., Bassirian, S., Singh, S., Faulkner, C., Bettencourt, R., Rizo, E., Richards, L., Xu, Z. Z., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09455-9 · Cited by 338 · cited 1×
“The same research group, in a very recent paper, identified the specific intestinal microflora profile of NAFLD cirrhotic patients, determining a panel of 27 fecal bacteria that may discriminate NAFLD cirrhosis using a random forest classifier model [65].”
BackgroundGut–liver axis, nutrition, and non-alcoholic fatty liver disease
Kirpich, I. A., Marsano, L. S., & McClain, C. J. (2015) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2015.06.023 · Cited by 327 · cited 1×
“The restoration of Bifidobacteria or Akkermansia muciniphila along with oligofructose implementation reduced endotoxemia, hepatic fat deposits and metabolic syndrome hallmarks in HFD mice [119].”
BackgroundIs butyrate the link between diet, intestinal microbiota and obesity-related metabolic diseases?
Brahe, L. K., Astrup, A., & Larsen, L. H. (2013) · Obesity Reviews · doi:10.1111/obr.12068 · Cited by 264 · cited 1×
“Microbial SCFAs may affect the intestinal barrier integrity and mucosal immune tolerance raising levels of intestinal SCFAs-producing species strengthen barrier integrity supporting tight junctions and mucins production and operating as energy source for intestinal mucosal cells [81,82].”
BackgroundThe Role of Intestinal Endotoxin in Liver Injury: A Long and Evolving History
Nolan, J. P. (2010) · Hepatology · doi:10.1002/hep.23917 · Cited by 229 · cited 1×
“Gut dysbiosis has been also causally linked to the pathogenesis of cirrhosis and progression to end-stage liver disease [47].”
BackgroundThe bile acid membrane receptor TGR5: a valuable metabolic target
Pols, T. W. H., Noriega, L. G., Nomura, M., Auwerx, J., & Schoonjans, K. (2011) · Digestive Diseases · doi:10.1159/000324126 · Cited by 185
Alcohol or gut microbiota: who is the guilty?
Meroni, M., Longo, M., & Dongiovanni, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184568 · Cited by 183 · cited 7×
“, Escherichia coli abundance), are able to stimulate hepatic Kupffer cells to produce pro-inflammatory cytokines with similar mechanisms occurring in ALD [10,57].”
BackgroundInfluentialGarcía‐Lezana, T., Raurell, I., Bravo, M., Torres‐Arauz, M., Salcedo, M. T., Santiago, A., Schoenenberger, A., Manichanh, C., Genescà, J., Martell, M., et al. (2018) · Hepatology · doi:10.1002/hep.29646 · Cited by 136
Román, E., Nieto, J. C., Gely, C., Vidal, S., Pozuelo, M., Poca, M., Juárez, C., Guarner, C., Manichanh, C., & Soriano, G. (2019) · Hepatology Communications · doi:10.1002/hep4.1325 · Cited by 80
The Intestinal Microbiome in Nonalcoholic Fatty Liver Disease
Puri, P., & Sanyal, A. J. (2018) · Clinics in Liver Disease · doi:10.1016/j.cld.2017.08.009 · Cited by 33
Cited by
Shaping the Future of Probiotics and Prebiotics
Cunningham, M., Azcarate-Peril, M. A., Barnard, A., Benoit, V., Grimaldi, R., Guyonnet, D., Holscher, H. D., Hunter, K., Manurung, S., Obis, D., et al. (2021) · Trends in Microbiology · doi:10.1016/j.tim.2021.01.003 · Cited by 637
Spermidine improves gut barrier integrity and gut microbiota function in diet-induced obese mice
Ma, L., Ni, Y., Wang, Z., Tu, W., Ni, L., Zhuge, F., Zheng, A., Hu, L., Zhao, Y., Zheng, L., et al. (2020) · Gut Microbes · doi:10.1080/19490976.2020.1832857 · Cited by 593
Novel therapeutic targets for cholestatic and fatty liver disease
Trauner, M., & Fuchs, C. D. (2022) · Gut · doi:10.1136/gutjnl-2021-324305 · Cited by 204
Naghipour, A., Amini-Salehi, E., Orang Gorabzarmakhi, M., Shahdkar, M., Fouladi, B., Alipourfard, I., & Sanat, Z. M. (2023) · Systematic Reviews · doi:10.1186/s13643-023-02299-x · Cited by 37
“Although there is no specific treatment for NAFLD, it is hoped microbial therapies, including probiotics, prebiotics, and synbiotics, will provide a new therapeutic method for the treatment by manipulating intestinal microbiota [28, 29].”
BackgroundMahapatro, A., Bawna, F., Kumar, V., Daryagasht, A. A., Gupta, S., Raghuma, N., Moghdam, S. S., Kolla, A., Mahapatra, S. S., Sattari, N., et al. (2023) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2023.07.087 · Cited by 37
Metadata
- Authors
- Meroni, M., Longo, M., & Dongiovanni, P.
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2019-11-04
- Volume
- 11
- Issue
- 11
- Pages
- 2642
- ISSN
- 2072-6643 (ISSN-L)
- OpenAlex
- W2987356494
- Cited by
- 140
- References
- 47
- FWCI
- 10.93
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.